Date Added: 20/03/2017
Date Updated: 20/03/2017
Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light (NB-UVB)
Specialties: Skin disease, burns and wound care
Technology Type: Drugs
Stage of development: Experimental - pilot or phase II
Stage of EAA: Prioritised for assessment
Generalised vitiligo: adults; stable or slowly progressing; with 10-50% of total body surface involvement – first line; in combination with narrow-band ultraviolet B light (NB-UVB).
Afamelanotide (SCENESSE; [Nle4,D-Phe7]-alpha-MSH; CUV-1647; EPT-1647; melanotan I; melanotan) is a structural analogue of endogenous alpha-melanocyte-stimulating hormone (α-MSH), which is formulated as a bioresorbable implant. Afamelanotide acts as an agonist at the melanocortin 1 receptor, activating the synthesis and transport of eumelanin. Afamelanotide may facilitate repigmentation and proliferation of melanocytes from melanocyte reservoirs and is also believed to have antioxidant and immunomodulatory properties.